Patients who underwent hormone therapy were associated with an increased risk of T2D development compared to patients not receiving hormone therapy (HR: 2.40 95% CI: 1.26–4.55), while Aromatase inhibitors were associated with the highest risk of T2D development (HR: 4.27, 95%CI 1.42–12.84).21 The gene discussed is CYP19A1; the disease is type 2 diabetes mellitus.